Moreover, CXCL10 suppresses myeloma by recruiting effector CD8+ T, CD4+ T, and NK cells to the tumor site, and combining CXCL10 with radiotherapy enhances its therapeutic efficacy in cervical cancer [81]. Here, CD4 is linked to plasma cell myeloma.